香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 趙炳祥（董事長） 陳啟宇 祖敬 邢永剛 陳玉卿 文德鏞 （於中華人民共和國註冊成立之股份有限公司， 在香港以國控股份有限公司之名稱經營業務） （股份代號：01099） 董事名單與其角色和職能 國藥控股股份有限公司董事會（「董事會」）成員載列如下： 非執行董事 俞衛鋒 石晟昊 陳威如 馮蓉麗 執行董事 連萬勇（總裁） 獨立非執行董事 李培育 吳德龍 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 1 董事會設立 5 個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | 董事 | 董事會委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | 戰略與投資 委員會 | 法律合規與 環境、社會及 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 治理委員會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 公告 建議更换執行董事 執行董事辭任 國藥控股股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，由於工作安 排原因，孫京林先生（「孫先生」）已於 2025 年 11月 6 日向董事會提出辭任執行董事及董事會戰略 與投資委員會（「戰略與投資委員會」）委員職務，上述辭任即時生效。 孫先生已確認其與董事會之間並無意見分歧，亦無任何與辭任有關之事宜須敬請本公司股東 （「股東」）及債權人關注。 孫先生在任職期間，恪盡職守，勤勉盡責。董事會藉此機會對其為本公司持續穩健發展及公司 治理水準不斷提升所作出的貢獻表示衷心感謝。 * 本公司以中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 建議委任執行董事 於同日，董事會決議建議委任楊秉華先生（「楊先生」）為執行董事（「建議委任董事」）。 建議委任董事乃根據本公司董事提名程序，由董事會提名委員會 ...

Core Viewpoint - China National Pharmaceutical Group (Sinopharm) is enhancing its strategic cooperation with leading global pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Eisai China, and Gilead Sciences through productive dialogues focused on current collaboration outcomes, future strategic alignment, and innovative business models [1] Group 1 - Sinopharm is engaging in effective discussions with multiple top-tier pharmaceutical firms [1] - The dialogues aim to inject new momentum into the ongoing strategic cooperation [1] - The focus includes exploring future strategic synergies and innovative business models [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) reported a decline in revenue and net profit for China National Pharmaceutical Industry (国药一致) in the first three quarters of 2025, indicating challenges in the current market environment [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 55.124 billion yuan, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was 0.957 billion yuan, reflecting a year-on-year decline of 10.18% [1] - Basic earnings per share stood at 1.72 yuan [1] Quarterly Performance - In the third quarter of 2025, the company reported a revenue of 18.328 billion yuan, which is a year-on-year decrease of 1.89% [1] - The net profit attributable to shareholders for the third quarter was 0.291 billion yuan, down 9.58% year-on-year [1]

Core Insights - China National Pharmaceutical Group (国药控股) reported a revenue of approximately RMB 18.328 billion for Q3 2025, representing a year-on-year decrease of 1.89% [1] - The net profit for the same period was around RMB 291 million, down 9.58% year-on-year [1] - Basic earnings per share stood at RMB 0.52 [1] Financial Performance - For the first three quarters of 2025, the total revenue was approximately RMB 55.124 billion, reflecting a year-on-year decline of 2.38% [1] - The net profit for the first three quarters was about RMB 957 million, which is a decrease of 10.18% compared to the previous year [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) reported a decline in revenue and net profit for the first three quarters of 2025, indicating challenges in the market [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 55.124 billion yuan, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was 0.957 billion yuan, down 10.18% year-on-year [1] - Basic earnings per share stood at 1.72 yuan [1] Quarterly Results - In the third quarter of 2025, the company recorded a revenue of 18.328 billion yuan, reflecting a year-on-year decline of 1.89% [1] - The net profit attributable to shareholders for the third quarter was 0.291 billion yuan, a decrease of 9.58% year-on-year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 茲提述國藥控股股份有限公司（「本公司」）於 2025 年 10 月 30 日刊發之海外監管公告 （「該公告」），內容有關本公司附屬公司國藥集團一致藥業股份有限公司（「國藥一 致」，其 A 股及 B 股在深圳證券交易所上市（A 股股票代碼：000028 及 B 股股票代碼： 200028））之 2025 年第三季度報告。 本公司董事會謹此提醒股東及公眾投資者注意以下於該公告內載列之國藥一致 2025 年第 三季度之主要未經審核會計數據和財務指標。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 國藥一致之主要未經審核會計數據和財務指標 （於中華人民共和國註冊成立之股份有限公司， 在香港以國控股份有限公司之名稱經營業務） 單位 : 元 （股份代號：01099） 幣種 : 人民幣 公告 國藥一致 2025年第三季度之 主要未經審核會計 ...

茲載列國藥控股股份有限公司旗下一間 A 股及 B 股於深圳證券交易所上市的附屬公 司，國藥集團一致藥業股份有限公司，在深圳證券交易所網站刊登的《國藥集團一 致藥業股份有限公司 2025 年第三季度報告》，僅供參閱。 （於中華人民共和國註冊成立之股份有限公司， 在香港以國控股份有限公司之名稱經營業務） （股份代號 ：01099） 海外監管公告 國藥集團一致藥業股份有限公司 2025 年第三季度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025年 10月 30日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先 生、祖敬先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李 培育先生、吳德龍先生、俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英 ...

Core Viewpoint - The company's performance for Q1 2025 aligns with expectations, showing a slight decline in revenue but stable net profit growth [1][2] Performance Review - For Q1 2025, the company reported revenue of 431.5 billion RMB, a year-on-year decrease of 2.5%, while net profit attributable to shareholders was 5.3 billion RMB, a year-on-year increase of 0.5%, meeting expectations [1] - In Q3 2025, the company achieved revenue of 145.4 billion RMB, a year-on-year decrease of 1.5% but a quarter-on-quarter increase of 0.7%. Net profit for the same period was 1.841 billion RMB, a year-on-year increase of 16.9% but a quarter-on-quarter decrease of 8.3% [1] Development Trends - The retail segment, particularly through subsidiary Guoda Pharmacy, saw revenue of 15.226 billion RMB in Q1 2025, a year-on-year decrease of 7.14%, but net profit improved significantly to 0.13 billion RMB, a year-on-year increase of 133.91% due to optimized procurement systems [1] - The medical device segment, represented by subsidiary China Medical Devices, reported revenue of 54.693 billion RMB in Q1 2025, a year-on-year decrease of 2.41%, with operating profit at 0.962 billion RMB, a year-on-year decrease of 10.34%, impacted by prescription volume from hospitals [1] Cost Structure - In Q1 2025, the company's gross margin was 7.2%, a year-on-year decrease of 0.2 percentage points. The sales expense ratio was 2.7%, a year-on-year decrease of 0.1 percentage points, while the management expense ratio was 1.1%, also down by 0.1 percentage points. Financial expense ratio remained stable at 0.4% [2] - For Q3 2025, the gross margin was stable at 7.5% year-on-year [2] Profit Forecast and Valuation - The company maintains net profit forecasts of 7.475 billion RMB for 2025 and 7.926 billion RMB for 2026, both reflecting a year-on-year growth of 6.0% [2] - The current stock price corresponds to a price-to-earnings ratio of 7.4 times for 2025 and 6.9 times for 2026, with a target price of 24.7 HKD, indicating a potential upside of 27.1% [2]

Core Viewpoint - The biotechnology and innovative pharmaceutical industry in China has experienced volatility due to previous overvaluation, uncertainty in national medical insurance drug pricing, delays in business expansion expectations, and year-end fund sell-offs [1] Group 1: Market Conditions - Market liquidity remains robust, making valuations of quality companies increasingly attractive [1] - Ongoing business expansion activities are noted, with the potential for large transactions still possible [1] - Further downside price risk appears limited, indicating a healthy consolidation phase [1] Group 2: Company-Specific Insights - For CSPC Pharmaceutical Group (01093), delays in business expansion execution have weakened investor confidence, creating more attractive buying opportunities [1] - Assuming business expansion resumes as expected, the price-to-earnings (P/E) valuation remains very attractive for CSPC [1] - The third-quarter performance may serve as a recent catalyst for CSPC [1] Group 3: Future Outlook - The likelihood of significant progress on large business expansion transactions is high for next year [1] - For China National Pharmaceutical Group (01099), improvements in accounts receivable days and the initiation of the "14th Five-Year Plan" will support the recovery of profit momentum [1] - Current stock price levels offer an appealing dividend yield and low P/E ratio, with significant upside potential as operational efficiency continues to improve [1]